Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Study Phase : Phase II/ Phase III
Sponsor : AstraZeneca
Deal Size : $1,050.0 million
Deal Type : Acquisition
AstraZeneca Closes Acquisition of Amolyt Pharma
Details : Through the acquisition, AstraZeneca leverages the AZP-3601 (neboparatide), peptide agonist of the PTH1 receptor. Currently, being evaluated for the treatment of Chronic Hypoparathyroidism.
Brand Name : AZP-3601
Molecule Type : Peptide
Upfront Cash : $800.0 million
July 15, 2024
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II/ Phase III
Sponsor : AstraZeneca
Deal Size : $1,050.0 million
Deal Type : Acquisition
Lead Product(s) : TOTUM•63
Therapeutic Area : Endocrinology
Study Phase : Phase II/ Phase III
Sponsor : Nestle Health Sciences SA
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TOTUM•63 is a unique and patented combination of 5 plant extracts that targets the pathophysiological mechanisms of type 2 diabetes. TOTUM•63 benefits from intellectual property validated by patents in the world's leading markets.
Brand Name : TOTUM•63
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 22, 2023
Lead Product(s) : TOTUM•63
Therapeutic Area : Endocrinology
Highest Development Status : Phase II/ Phase III
Sponsor : Nestle Health Sciences SA
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Totum-63
Therapeutic Area : Endocrinology
Study Phase : Phase II/ Phase III
Sponsor : INAF
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TOTUM-63 is a unique and patented combination of 5 plant extracts that targets the pathophysiological mechanisms of type 2 diabetes, has already been shown to be safe and effective in healthy volunteers in a Phase I/II clinical study.
Brand Name : Totum-63
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 29, 2022
Lead Product(s) : Totum-63
Therapeutic Area : Endocrinology
Highest Development Status : Phase II/ Phase III
Sponsor : INAF
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nicotinamide Riboside Chloride
Therapeutic Area : Endocrinology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ChromaDex has invested over $35 million in investigating and marketing NR as Niagen, which has received regulatory acceptance in the United States, Canada, the European Union, and Australia.
Brand Name : Niagen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 17, 2020
Lead Product(s) : Nicotinamide Riboside Chloride
Therapeutic Area : Endocrinology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Totum-63
Therapeutic Area : Endocrinology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : EASD has selected the positive results of the international Phase II clinical study on TOTUM-63 in prediabetes to be presented next September in its 56th annual meeting. These results were selected by the American Diabetes Association last June 2020.
Brand Name : Totum-63
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 21, 2020
Lead Product(s) : Totum-63
Therapeutic Area : Endocrinology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Totum-63
Therapeutic Area : Endocrinology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The REVERSE-IT study will include 600 patients with fasting hyperglycemia ranging from prediabetes to untreated early stage Type 2 Diabetes. The study should confirm the efficacy of TOTUM-63 - at a dose of 5g/day for 6 months.
Brand Name : Totum-63
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 15, 2020
Lead Product(s) : Totum-63
Therapeutic Area : Endocrinology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?